Bioceres Crop Solutions Corp. (BIOX) Cash Flow Statement
Where BIOX’s cash came from and went, FY2025
June 30, 2025 · U.S. dollars- Cash from operations
- $49.9M +19.6% vs FY2024
- Capital expenditures
- $14.6M 4.4% of revenue
- Free cash flow
- $35.3M 10.6% margin
- Returned to shareholders
- $926,899 3% of free cash flow
- Change in cash
- −$11.8M cash at year-end $32.7M
Drawn to scale: where the cash came from and how it was used. Hover for values.
BIOX operating cash flow, capex and free cash flow
BIOX cash flow trends, FY2016–FY2025
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Operating cash flow | −$1.1MFY2016 | $49.9MFY2025 | — | |
| Capital expenditures | $1.2MFY2016 | $14.6MFY2025 | +32.0%/yr | |
| Free cash flow | −$1.1MFY2016 | $35.3MFY2025 | — | |
| Free cash flow margin | −21.9%FY2016 | 10.6%FY2025 | +32.5 pts | |
| Operating cash flow / net income | 2.20FY2020 | 5.72FY2024 | +3.52 | |
| Stock-based compensation | $3,285FY2016 | $4.4MFY2025 | +122.5%/yr | |
| Dividends paid | $13,790FY2016 | $0FY2025 | −100.0% | |
| Share buybacks (net) | $0FY2016 | $926,899FY2025 | — | |
| Capex / revenue | 23.6%FY2016 | 4.4%FY2025 | −19.2 pts |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
BIOX cash flow by activity
BIOX net income vs operating cash flow
Operating cash flow above net income usually means earnings are backed by cash (depreciation and stock-based pay are non-cash expenses).
BIOX cash flow statement
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating activities | ||||||||||
| Net income | −$58.8M | $7.3M | $20.2M | −$3.9M | −$3.8M | $4.2M | −$16.4M | −$14.3M | −$11.8M | −$1.2M |
| Depreciation & amortization | $22.2M | $21.3M | $19.4M | $9.2M | $6.3M | $4.7M | $4.8M | $4.4M | $4.6M | $73,608 |
| Stock-based compensation | $4.4M | $14.1M | $3.4M | $1.4M | $1.7M | $3.4M | −$102,827 | $30,005 | $51,420 | $3,285 |
| Change in working capital | $19.3M | −$41.5M | −$85.1M | −$60.9M | −$53.9M | −$38.8M | −$11.4M | −$8.1M | $41.5M | −$2.4M |
| Other non-cash items | $62.9M | $40.5M | $44.7M | $36.6M | $43.6M | $35.7M | $52.8M | $36.4M | −$15.2M | $2.4M |
| Cash from operating activities | $49.9M | $41.7M | $2.6M | −$17.5M | −$6.2M | $9.3M | $29.7M | $18.4M | $19.1M | −$1.1M |
| Investing activities | ||||||||||
| Capital expenditures | −$14.6M | −$22.8M | −$22.6M | −$9.0M | −$13.9M | −$4.5M | −$3.4M | −$5.7M | −$1.4M | −$1.2M |
| Investments (net) | −$6.1M | −$28.7M | −$25.7M | −$25.7M | $10.3M | $4.9M | −$22.2M | −$129,340 | −$129,340 | — |
| Acquisitions & other investing | $14.6M | $22.8M | $22.6M | $37.6M | −$4.7M | −$8.2M | $22.4M | −$2.4M | −$18.6M | $1.2M |
| Cash from investing activities | −$6.1M | −$28.7M | −$25.7M | $2.9M | −$8.3M | −$7.8M | −$3.3M | −$8.2M | −$20.2M | −$5,594 |
| Financing activities | ||||||||||
| Dividends paid | $0 | $0 | $0 | $0 | −$1.0M | $0 | $0 | $0 | $0 | −$13,790 |
| Share repurchases & issuance (net) | −$926,899 | −$734,388 | −$3.0M | −$3.0M | −$3.5M | −$30,906 | −$30,906 | $0 | $0 | $42.0M |
| Net borrowing (repayment) | −$27.6M | $18.3M | $59.2M | $59.2M | $15.7M | $13.3M | $31.3M | −$8.7M | $4.5M | — |
| Shares issued | $0 | $0 | $0 | $0 | $0 | $0 | $112.7M | $0 | $0 | $0 |
| Other financing | −$22.2M | −$27.6M | −$23.3M | −$41.4M | −$3.8M | $20.3M | −$170.9M | −$1.8M | −$2.1M | −$40.9M |
| Cash from financing activities | −$50.7M | −$10.1M | $33.0M | $14.8M | $7.4M | $33.5M | −$26.9M | −$10.5M | $2.3M | $1.1M |
| Summary | ||||||||||
| Net change in cash | −$11.8M | −$3.7M | $14.7M | −$2.6M | −$6.5M | $39.1M | $1.2M | $535,625 | $1.4M | −$16,167 |
| Cash at end of period | $32.7M | $44.5M | $48.1M | $33.5M | $36.0M | $42.5M | $3.5M | $2.2M | $2.4M | $20,524 |
| Free cash flow | $35.3M | $18.9M | −$20.0M | −$26.5M | −$20.1M | $4.8M | $26.2M | $12.7M | $17.7M | −$1.1M |
| Free cash flow margin | 10.6% | 4.1% | −4.8% | −8.1% | −9.7% | 2.8% | 16.4% | 9.5% | 18.9% | −21.9% |
| Capex / revenue | 4.4% | 4.9% | 5.4% | 2.7% | 6.7% | 2.6% | 2.2% | 4.3% | 1.5% | 23.6% |
| Operating cash flow / net income | — | 5.72 | 0.13 | — | — | 2.20 | — | — | — | — |
| Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | Jun '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating activities | |||||||||||
| Net income | −$1.8M | −$7.4M | −$44.3M | −$10.1M | $9.1M | −$6.2M | −$1.5M | $9.8M | $1.2M | −$2.7M | −$2.8M |
| Depreciation & amortization | $1.2M | $5.8M | $4.9M | $10.7M | $1.2M | $5.3M | $6.6M | $4.9M | $4.9M | $4.8M | $4.4M |
| Stock-based compensation | −$533 | $533 | $1.0M | $1.1M | $1.4M | $809,585 | $2.7M | $3.0M | $2.3M | $6.2M | $734,890 |
| Change in working capital | $9.0M | −$2.9M | $29.1M | $24.8M | −$30.7M | −$3.9M | $7.4M | −$38.2M | −$551,139 | −$4.1M | −$22.2M |
| Other non-cash items | $9.0M | $18.9M | $36.0M | −$3.3M | $13.7M | $9.1M | $8.2M | $3.1M | $13.2M | $10.5M | $11.4M |
| Cash from operating activities | $17.4M | $14.4M | $26.8M | $23.3M | −$5.4M | $5.2M | $23.3M | −$17.4M | $21.1M | $14.7M | −$8.5M |
| Investing activities | |||||||||||
| Capital expenditures | −$216,107 | −$1.4M | −$2.2M | −$5.9M | −$3.4M | −$3.1M | −$2.0M | −$6.0M | −$4.7M | −$6.0M | −$6.6M |
| Investments (net) | −$538,109 | −$1.3M | $1.5M | −$2.5M | −$5.4M | $271,763 | −$295,058 | −$1.4M | −$18.4M | −$2.7M | −$3.2M |
| Acquisitions & other investing | −$2.0M | $1.4M | — | $5.9M | $3.4M | $3.1M | — | $6.0M | $4.7M | $35,682 | $6.6M |
| Cash from investing activities | −$2.8M | −$1.3M | — | −$2.5M | −$5.4M | $271,763 | — | −$1.4M | −$18.4M | −$8.7M | −$3.2M |
| Financing activities | |||||||||||
| Dividends paid | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | — |
| Share repurchases & issuance (net) | — | — | $0 | $0 | −$926,899 | $0 | $0 | $0 | −$277,303 | −$457,085 | −$483,160 |
| Net borrowing (repayment) | −$13.3M | −$24.3M | −$22.5M | −$8.6M | $16.4M | −$12.9M | — | — | — | −$21.2M | $21.6M |
| Shares issued | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other financing | −$4.7M | −$4.4M | −$3.2M | −$4.1M | −$9.0M | −$5.9M | $5.3M | $10.9M | $976,000 | −$5.3M | −$17.8M |
| Cash from financing activities | −$18.0M | −$28.7M | −$25.7M | −$12.7M | $6.5M | −$18.8M | $5.3M | $10.9M | $698,697 | −$27.0M | $3.3M |
| Summary | |||||||||||
| Net change in cash | −$4.4M | −$17.2M | −$38.5M | $13.4M | −$7.2M | −$12.2M | $28.1M | −$8.0M | −$4.0M | −$19.8M | −$9.6M |
| Cash at end of period | $11.1M | $15.5M | $32.7M | $38.5M | $25.0M | $32.3M | $44.5M | $16.4M | $24.4M | $28.4M | $48.1M |
| Free cash flow | $17.2M | $13.0M | $24.6M | $17.4M | −$8.7M | $2.0M | $21.2M | −$23.4M | $16.4M | $8.7M | −$15.1M |
| Free cash flow margin | 23.3% | 16.8% | 33.0% | 29.2% | −8.8% | 2.2% | 17.1% | −27.8% | 11.7% | 7.5% | — |
| Capex / revenue | 0.3% | 1.8% | 2.9% | 9.9% | 3.4% | 3.4% | 1.6% | 7.1% | 3.4% | 5.2% | — |
| Operating cash flow / net income | — | — | — | — | −0.59 | — | — | −1.78 | 17.05 | — | — |
Negative numbers are cash paid out. Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported; data from EODHD.
BIOX cash generation
In fiscal 2025 (ended June 30, 2025), Bioceres Crop Solutions generated $49.9 million of cash from operations (up 19.6%) and spent $14.6 million on capital expenditures, leaving free cash flow of $35.3 million, 10.6% of revenue. It returned $0.9 million to shareholders through dividends ($0) and net share buybacks ($0.9 million). Cash and equivalents fell by $11.8 million over the year.
Related: BIOX income statement, BIOX balance sheet. See the BIOX stock overview for the latest quote and news.
BIOX cash flow FAQ
What is Bioceres Crop Solutions's free cash flow?
Bioceres Crop Solutions's free cash flow was $35.3 million in fiscal 2025: $49.9 million of operating cash flow minus $14.6 million of capital expenditures It was $18.9 million a year earlier..
How much cash does Bioceres Crop Solutions generate from operations?
Bioceres Crop Solutions generated $49.9 million of cash from operating activities in fiscal 2025.
How much does Bioceres Crop Solutions spend on capital expenditures?
Bioceres Crop Solutions spent $14.6 million on capital expenditures in fiscal 2025, 4.4% of revenue, compared with $22.8 million the year before.
How much stock does Bioceres Crop Solutions buy back?
Bioceres Crop Solutions spent $0.9 million on net share repurchases in fiscal 2025.